Randomised trials relevant to mental health conducted in low and middle-income countries: a survey

Syed Sheriff, Rebecca J.; Adams, Clive E.; Tharyan, Prathap; Jayaram, Mahesh; Duley, Lelia
January 2008
BMC Psychiatry;2008, Vol. 8, Special section p1
Academic Journal
Background: A substantial proportion of the psychiatric burden of disease falls on the world's poorest nations, yet relatively little is known about randomised trials conducted in these countries. Our aim was to identify and describe a representative sample of mental health trials from low and middle-income countries. Methods: 6107 electronic records, most with full text copies, were available following extensive searches for randomised or potentially randomised trials from low and middle-income countries published in 1991, 1995 and 2000. These records were searched to identify studies relevant to mental health. Data on study characteristics were extracted from the full text copies. Results: Trials relevant to mental health were reported in only 3% of the records. 176 records reporting 177 trials were identified: 25 were published in 1991, 45 in 1995, and 106 in 2000. Participants from China were represented in 46% of trials described. 68% of trials had <100 participants. The method of sequence generation was described in less than 20% of reports and adequate concealment of allocation was described in only 12% of reports. Participants were most frequently adults with unipolar depression (36/177) or schizophrenia (36/177). 80% of studies evaluated pharmacological interventions, a third of which were not listed by WHO as essential drugs. 41% of reports were indexed on PubMed; this proportion decreased from 68% in 1991 to 32% in 2000. Conclusion: In terms of overall health burden, trial research activity from low and middle-income countries in mental health appears to be low, and in no area adequately reflects need.


Related Articles

  • Quetiapine in the Long-Term Treatment of Schizophrenia.  // Child & Adolescent Psychopharmacology News;Aug2004, Vol. 9 Issue 5, p10 

    The article examines the long-term potency and safety of quetiapine in patients with schizophrenia using joint data from the open-label extension (OLE) of four Phase IIIa trials. The eligible patients that were selected for this study were from Europe, Canada and South Africa, and OLE phases...

  • Cost of scaling up mental healthcare in low- and middle-income countries. Chisholm, Dan; Lund, Crick; Saxena, Shekhar // British Journal of Psychiatry;Dec2007, Vol. 191, p528 

    Background: No systematic attempt has been made to calculate the costs of scaling up mental health services in low- and middle-income countries.Aims: To estimate the expenditures needed to scale up the delivery of an essential mental healthcare package over a 10-year...

  • Schizophrenia and depression. Bosanac, Peter; Castle, David J // Medical Journal of Australia;Oct2013 Supplement S8, Vol. 199, pS36 

    Summary: Depressive symptoms are common in people with schizophrenia and can be associated with suicidality, but are often either missed or dismissed by clinicians.General practitioners have a key role in initial assessment and subsequent monitoring of depressive symptoms, associated risks and...

  • Matching up treatments for chronic schizophrenia is a challenge. Wynn, Paul // Drug Topics;3/6/2006, Vol. 150 Issue 5, p5s 

    The article focuses on the challenges in selecting the pharmacologic options for the treatments of chronic schizophrenia in the U.S. The National Institute of Mental Health undertook the largest independent trial to compare existing treatments for major psychiatric illnesses. The program...

  • Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Meijer, Carin J.; Koeter, Maarten W. J.; Sprangers, Mirjam A. G.; Schene, Aart H. // Social Psychiatry & Psychiatric Epidemiology;May2009, Vol. 44 Issue 5, p361 

    The concept ‘quality of life’ (QoL) has become increasingly important as an outcome measure in the evaluation of services and in clinical trials of people with schizophrenia. This study examines the mediating role of health related quality of life (HRQoL) in the prediction of...

  • Randomized Clinical Trials to Evaluate Mental Health Interventions in Resource-Poor Societies. Neugebauer, Richard // JAMA: Journal of the American Medical Association;12/27/2016, Vol. 316 Issue 24, p2601 

    An introduction is presented in which the author discusses information in the issue on two randomized clinical trials (RCTs) that evaluate the effectiveness of mental health interventions in developing societies.

  • Two-year outcome of children treated for depression. Vostanis, P.; Feehan, C.; Grattan, E. // European Child & Adolescent Psychiatry;1998, Vol. 7 Issue 1, p12 

    Abstract Fifty-four children and adolescents (age 8-17) were assessed two years after a clinical intervention trial of cognitive-behavioural vs. non-focused treatment for depression. Eleven (20.4%) subjects fulfilled criteria for depression, while 21 (38.9%) reported significant depressive...

  • Treatment of adolescents with depression: the effect of transference interventions in a randomized controlled study of dynamic psychotherapy. Ulberg, Randi; Grete Hersoug, Anne; H›glend, Per // Trials;2012, Vol. 13 Issue 1, p159 

    Background: Depression in adolescents seems to be a growing problem that causes mental suffering and prevents young people from joining the workforce. There is also a high risk of relapse during adult life. There is emerging evidence for the effect of psychodynamic psychotherapy in adolescents....

  • The InterHerz project - a web-based psychological treatment for cardiac patients with depression: study protocol of a randomized controlled trial. Messerli-Brgy, Nadine; Barth, Jrgen; Berger, Thomas // Trials;2012, Vol. 13 Issue 1, p245 

    Background: Patients with heart disease often suffer from difficulties in psychological adaptation during cardiac rehabilitation. Mood disorders such as depression are known to be highly prevalent in cardiac patients and to have a negative impact on the progression of coronary heart disease....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics